KR102399254B1 - 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 - Google Patents

비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 Download PDF

Info

Publication number
KR102399254B1
KR102399254B1 KR1020197011062A KR20197011062A KR102399254B1 KR 102399254 B1 KR102399254 B1 KR 102399254B1 KR 1020197011062 A KR1020197011062 A KR 1020197011062A KR 20197011062 A KR20197011062 A KR 20197011062A KR 102399254 B1 KR102399254 B1 KR 102399254B1
Authority
KR
South Korea
Prior art keywords
ubenimex
administered
nash
pharmaceutical composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197011062A
Other languages
English (en)
Korean (ko)
Other versions
KR20190058532A (ko
Inventor
샤오펭 시옹
데이비드 에이. 코리
Original Assignee
아이거 바이오파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이거 바이오파마슈티컬스 인코포레이티드 filed Critical 아이거 바이오파마슈티컬스 인코포레이티드
Publication of KR20190058532A publication Critical patent/KR20190058532A/ko
Application granted granted Critical
Publication of KR102399254B1 publication Critical patent/KR102399254B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197011062A 2016-09-28 2017-09-28 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 Expired - Fee Related KR102399254B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662400963P 2016-09-28 2016-09-28
US62/400,963 2016-09-28
US201762460606P 2017-02-17 2017-02-17
US62/460,606 2017-02-17
US201762469722P 2017-03-10 2017-03-10
US62/469,722 2017-03-10
PCT/US2017/054087 WO2018064373A1 (en) 2016-09-28 2017-09-28 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (2)

Publication Number Publication Date
KR20190058532A KR20190058532A (ko) 2019-05-29
KR102399254B1 true KR102399254B1 (ko) 2022-05-17

Family

ID=61760848

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011062A Expired - Fee Related KR102399254B1 (ko) 2016-09-28 2017-09-28 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물

Country Status (6)

Country Link
US (2) US10588880B2 (https=)
EP (1) EP3518918A4 (https=)
JP (1) JP7022136B2 (https=)
KR (1) KR102399254B1 (https=)
CN (1) CN109862888B (https=)
WO (1) WO2018064373A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518918A4 (en) 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
CA3101274A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
EP3811937A1 (en) * 2019-10-24 2021-04-28 Sorbonne Universite Compounds for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303548A1 (en) 2010-11-22 2013-11-14 The Regents Of The University Of California Indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
US20150209314A1 (en) 2011-12-08 2015-07-30 Medicinova, Inc. Method of treating liver disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052449A (en) 1974-07-01 1977-10-04 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
JPH0759507B2 (ja) * 1989-02-23 1995-06-28 日本化薬株式会社 骨髄異形成症候群治療剤
CN1098249C (zh) 1995-06-21 2003-01-08 国家医药管理局四川抗菌素工业研究所 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
JP5133071B2 (ja) * 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
JP2009109426A (ja) * 2007-10-31 2009-05-21 Sysmex Corp 検体前処理液、ウイルス測定用キット及びウイルス検出方法
US9233089B2 (en) 2012-03-23 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
CN104902921A (zh) * 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
DK3043865T3 (da) * 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
SI3077047T1 (sl) * 2013-12-04 2019-09-30 Galmed Research & Development Ltd. Soli aramchola
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104784178B (zh) * 2015-05-08 2017-04-12 重庆医科大学 尼克酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
CN104887655A (zh) * 2015-06-12 2015-09-09 上海来益生物药物研究开发中心有限责任公司 乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
EP3518918A4 (en) 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
EP3716975A4 (en) 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303548A1 (en) 2010-11-22 2013-11-14 The Regents Of The University Of California Indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
US20150209314A1 (en) 2011-12-08 2015-07-30 Medicinova, Inc. Method of treating liver disorders

Also Published As

Publication number Publication date
JP7022136B2 (ja) 2022-02-17
CN109862888A (zh) 2019-06-07
US20190307714A1 (en) 2019-10-10
CN109862888B (zh) 2022-08-12
JP2019529566A (ja) 2019-10-17
US10588880B2 (en) 2020-03-17
WO2018064373A1 (en) 2018-04-05
US20200237696A1 (en) 2020-07-30
EP3518918A4 (en) 2020-04-22
KR20190058532A (ko) 2019-05-29
EP3518918A1 (en) 2019-08-07
US11571403B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
KR102399254B1 (ko) 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
AU2013259526B2 (en) New methods
US10449154B2 (en) Treatment of NASH with Gemcabene
US20190111017A1 (en) Compositions and Methods for Treating Non-Alcoholic Steatohepatitis
KR20120047891A (ko) Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
KR20230015884A (ko) 비알코올성 지방간염 치료를 위한 세마글루타이드
CN111093705A (zh) 包含fxr激动剂的组合
TW201815420A (zh) 使用fxr促效劑之方法
CA3082178A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
US20230181602A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
BRPI0707670A2 (pt) composiÇço farmacÊutica, e, uso de um composto meglitinida
TW202210081A (zh) 非酒精性脂肪肝炎（ｎａｓｈ）之治療
WO2021097027A1 (en) Seladelpar for use in the treatment of alcoholic liver disease
TW202214256A (zh) 非酒精性脂肪肝炎（ｎａｓｈ）之治療
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250514

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250514

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250514